Loading
Life sciences · Journal article
Drug Development Research · August 17, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is a preclinical mechanistic study demonstrating that dioscin directly binds AKT1 and suppresses AKT/GSK3β signaling to promote P-gp degradation and reverse EMT in paclitaxel-resistant cancer cell lines, with confirmatory in vivo xenograft data. The work is exploratory, establishes a putative mechanism, and does not include clinical efficacy, comparative efficacy against standard therapy, or human safety data.
Preclinical mechanistic study with in vitro cell line models and in vivo xenograft validation. Paclitaxel-resistant human cancer cell lines (TE-1/PTX from esophageal cancer, HeLa/PTX from cervical cancer); nude mice bearing HeLa/PTX xenografts.. Intervention: Dioscin (a natural steroidal saponin), administered in vitro to resistant cell lines and in vivo to xenograft-bearing mice.. Compared with: No formal comparator arm; paclitaxel alone and vehicle control implied but not formally described as a comparative group..
Dioscin sensitized PTX-resistant TE-1/PTX and HeLa/PTX cells to paclitaxel and increased intracellular Rh123 accumulation, indicating restored drug uptake. Dioscin directly bound AKT1 and suppressed AKT/GSK3β signaling, promoting ubiquitin-proteasomal degradation of P-gp. Dioscin inhibited cell migration and invasion and reversed EMT by upregulating epithelial markers and repressing mesenchymal markers and EMT transcription factors.
Toxicity described only as 'negligible systemic toxicity' without quantitative safety data, organ weight, or clinical chemistry. In vivo, dioscin restrained xenograft tumor growth with negligible systemic toxicity, and intratumoral protein expression patterns mirrored in vitro findings.
This work provides a mechanistic rationale for investigating dioscin in drug-resistant cancers, but is not yet suitable for clinical translation. Human Phase 1 safety and efficacy studies would be required before any clinical recommendation.
Mechanistic study in resistant cell lines with in vivo xenograft validation, but no clinical trial data, no comparative chemotherapy arm, and no human efficacy or safety evidence.
As stated by the source record.
Quoted from the source exactly as published.
This work provides a mechanistic rationale for investigating dioscin in drug-resistant cancers, but is not yet suitable for clinical translation. Human Phase 1 safety and efficacy studies would be required before any clinical recommendation.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
ABSTRACT Tumor drug resistance and metastasis are leading causes of cancer‑related mortality, both of which are tightly governed by multiple signaling pathways. The AKT‑GSK‑3β axis is a critical regulator of tumor progression, mediating drug resistance and epithelial‑mesenchymal transition (EMT) through its downstream targets. Aberrantly activated AKT‑GSK‑3β signaling modulates the expression and degradation of the drug efflux pump P‐gp, which expels chemotherapeutic agents, including paclitaxel (PTX), from cancer cells, resulting in chemotherapy failure and drug resistance. Moreover, hyperactivated AKT‑GSK‑3β signaling drives EMT, a key process closely linked to tumor metastasis and malignant progression. Dioscin (Dio), a natural steroidal saponin, exhibits significant anti‑tumor activity in multiple cancers. However, whether Dio reverses chemoresistance and inhibits tumor growth by targeting the AKT‑GSK‑3β pathway to promote P‐gp degradation and suppress EMT remains elusive, which is the central focus of this study. To explore whether Dio enhances the sensitivity of drug‐resistant cancer cells to PTX and inhibits cancer metastasis and the EMT process, as well as its potential mechanism(s). Paclitaxel‐resistant TE‐1/PTX and HeLa/PTX cells were subjected to SRB, colony formation, Rh123 accumulation, wound‐healing, and Transwell assays to evaluate Dio's chemosensitizing, anti‐EMT, and anti‐metastatic effects. Network pharmacology, molecular docking, CETSA, and proteolysis assays verified a direct Dio‐AKT1 interaction. Western blotting, Co‐IP, and MG132 and MK2206 rescue experiments clarified AKT/GSK3β‐dependent P‐gp ubiquitin‐proteasomal degradation and EMT suppression. HeLa/PTX xenograft models were generated; H&E staining and immunoblotting were used to assess tumor growth, biosafety, and intratumoral protein profiles for in vivo validation. Dio sensitized PTX‐resistant cells to paclitaxel, increased intracellular Rh123 accumulation, and inhibited cell migration and invasion. Mechanistically, Dio directly bound AKT1 to suppress AKT/GSK3β signaling, promoted ubiquitin‐proteasomal degradation of P‐gp, and reversed EMT by upregulating epithelial markers and repressing mesenchymal markers and EMT transcription factors. In vivo, Dio restrained xenograft tumor growth with negligible systemic toxicity, and intratumoral expression patterns of AKT/GSK3β, P‐gp, and EMT‐related proteins mirrored in vitro findings. Dio has the potential to be a safe and effective agent for drug‐resistant cancer therapy.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.